Clinical Trials

44 enrolled

Rectal Cancer Patients

NCT07505186 2026-04-01

Camrelizumab, Chemotherapy and Ivarmacitinib in Patients With Resectable Esophageal Squamous Cell Carcinoma

45 enrolled

Phase NA Not yet recruiting

Esophageal Squamous Cell Carcinoma

NCT07466901 2026-03-12

A Single-arm, Multicenter, Phase II Clinical Study of Camrelizumab Combined With Famitinib in Adjuvant Therapy After Radical Resection of Cervical Cancer

30 enrolled

Gynecologic

Uterine Cervical Neoplasms

NCT07432087 2026-02-25

Camrelizumab Combined With EGFR Monoclonal Antibody or Chemotherapy for Perioperative Treatment of Locally Advanced Head and Neck Squamous Cell Carcinoma

Phase 3 Not yet recruiting

246 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck

NCT07400094 2026-02-10

NeoCamre-HN

50 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck, Laryngeal Neoplasms, Mouth Neoplasms

NCT07395063 2026-02-09

A Clinical Study on the Treatment of Metastatic Colorectal Cancer at the Second-line or Beyond.

68 enrolled

Colorectal Neoplasms

NCT07314372 2026-01-20

FAD-HCC-001

86 enrolled

Carcinoma, Hepatocellular

NCT07324473 2026-01-07

Ivarmacitinib Combined With Camrelizumab and Apatinib for Unresectable Advanced Hepatocellular Carcinoma With Acquired Resistance to Immune Checkpoint Therapy: A Single-Arm Exploratory Clinical Study

65 enrolled

Phase 2/3 Not yet recruiting

Carcinoma, Hepatocellular

NCT07309419 2025-12-30

Cocktail-001

222 enrolled

Carcinoma, Hepatocellular

NCT07143292 2025-11-18

A Prospective, Randomized, Parallel Trial of Famitinib Malate at Different Doses Combined With Camrelizumab for the Treatment of Recurrent and Metastatic Cervical Cancer

120 enrolled

Gynecologic

Cervical Cancer Metastatic

NCT07191977 2025-09-25

Neoadjuvant Camrelizumab With Palbociclib for Resectable Esophageal Squamous Cell Carcinoma

41 enrolled

Esophageal Squamour Cell Cancer

NCT07159217 2025-09-08

Disitamab Vedotin Plus Lenvatinib and PD-1 Inhibitors for Treating HER2-positive Advanced Biliary Tract Cancer

65 enrolled

Biliary Tract Neoplasms

NCT07107217 2025-08-17

Camella

40 enrolled

Breast Neoplasms

NCT06196671 2025-08-07

PTCA199-8

30 enrolled

Phase NA Not yet recruiting

Pancreatic Neoplasms

NCT07067450 2025-07-16

Adjuvant Immunotherapy for Esophageal Squamous Cell Carcinoma

98 enrolled

Esophageal Squamous Cell Carcinoma

NCT06632405 2025-03-26

A Trial of Camrelizumab Plus Nab-paclitaxel and Levocetirizine in Metastatic or Recurrent TNBC

60 enrolled

Breast Neoplasms

NCT06849492 2025-02-27

SHIFT-001

120 enrolled

Advanced Triple Negative Breast Cancer

NCT06759090 2025-01-06

Metronomic Capecitabine with Camrelizumab and Apatinib Mesylate for Treatment of Advanced Pancreatic Cancer

43 enrolled

Pancreatic Neoplasms

NCT06731153 2024-12-12

JAK1 Inhibitor Ivarmacitinib Reversing Immunotherapy Resistance in TNBC

40 enrolled

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT06694324 2024-11-19

First-line Treatment of Advanced/unresectable DDLPS

49 enrolled

Sarcoma

Liposarcoma, Sarcoma

NCT06692491 2024-11-18

SPRING

200 enrolled

Rare Tumour

NCT06632522 2024-10-09

Clinical Study of Radiotherapy Combined With Camrelizumab and Apatinib in the Treatment of Liver Cancer Patients .

46 enrolled

Liver Neoplasms

NCT06546280 2024-08-09

A Study of Camrelizumab Plus Apatinib as Adjuvant Therapy in Patients With Hepatocellular Carcinoma at High Risk of Recurrence After Radical Resection or Ablation

38 enrolled

Phase 1 Not yet recruiting

Carcinoma, Hepatocellular

NCT06530082 2024-07-31

A Single Arm Clinical Study of Dendritic Cell Vaccine Loaded With Circular RNA Encoding Cryptic Peptide for Patients With HER2-negative Advanced Breast Cancer

48 enrolled

Breast Neoplasms

NCT06423937 2024-05-21

Fruquintinib Plus Camrelizumab and HAIC in the Treatment of Non-MSI-H Advanced Colorectal Cancer

129 enrolled

Colorectal Neoplasms

NCT06329947 2024-05-08

A Phase II Study of Surufatinib Combined With Camrelizumab and mFOLFOX6 as Second-line Treatment for Advanced PRAD

37 enrolled

Phase 2/3 Not yet recruiting

Advanced Pancreatic Cancer

NCT06335355 2024-03-28

A Phase II/III Study of Adebrelimab in Combination With SHR-8068 and Chemotherapy in Advanced or Metastatic NSCLC Patients

401 enrolled

Thoracic

Non-squamous Non-small Cell Lung Cancer

NCT06304545 2024-03-12

Treatment of Rectal Cancer With Long-term Concurrent Chemoradiotherapy Combined With Camrelizumab

48 enrolled

Phase 4 Not yet recruiting

Rectal Neoplasms

NCT06276933 2024-02-26

A Study of Camrelizumab Combined With Chemotherapy ± Thalidomide in First-line Treatment of Patients With Advanced Non-small Cell Lung Cancer (NSCLC)

104 enrolled

Thoracic

Lung Neoplasms

NCT06124001 2023-11-15

Clinical Study of VG161 Combined With Camrelizumab in Patients With Advanced Primary Hepatocellular Carcinoma

Phase 1/2 Not yet recruiting

36 enrolled

Phase 1/2 Not yet recruiting

Carcinoma, Hepatocellular

NCT06010212 2023-08-24

Fruquintinib as First Line Treatment in Patients With Recurrent Esophageal Squamous Cell Carcinoma

36 enrolled

Esophageal Squamous Cell Carcinoma

NCT05821452 2023-04-20

Immunotherapy Plus Chemotherapy vs. Chemoradiotherapy for Thoracic Squamous Esophageal Carcinoma

Phase 3 Not yet recruiting

40 enrolled

Chemotherapy

NCT05610332 2022-11-09

Clinical Efficacy in Neoadjuvant Treatment of Locally Advanced Gastric Cancer With Different Immunotypes

216 enrolled

Locally Advanced Gastric Cancer

NCT05550558 2022-09-28

CAN-RESPOND

43 enrolled

Gynecologic

Endometrial Neoplasms

NCT05524974 2022-09-01

Clinical Study of Camrelizumab, Apatinib Mesylate and Nab-paclitaxel Combined With Oxplatin and S-1 in the Neoadjuvant Treatment of Locally Advanced Gastric Cancer With Different Genotypes

203 enrolled